Aim Immunotech INC 8-K filings

AIM ImmunoTech CEO Thomas K. Equels published an article in Breaking Defense discussing the potential of Ampligen as a broad-spectrum antiviral for biodefense applications, including Ebola and coronaviruses.

AIM ImmunoTech reported second quarter 2026 financial results, noting increased cash reserves and reduced R&D expenses, while advancing its Ampligen pancreatic cancer Phase 2 trial towards Phase 3 development.

AIM ImmunoTech has entered into a proposal agreement with Sterling Pharma Solutions for the manufacturing of drug substances to support ongoing and future clinical trials.

AIM ImmunoTech Inc. has mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026, ceasing its at-the-market offering program.

AIM ImmunoTech Inc. held a Special Meeting of Stockholders on July 15, 2026, where shareholders approved several proposals related to stock issuance and a potential reverse stock split.

AIM ImmunoTech has regained compliance with NYSE American continued listing standards, resolving stockholder equity deficiencies through recent capital raises.

AIM ImmunoTech Inc. announced a registered direct offering and concurrent private placement raising approximately $2.65 million, including the issuance of Class J warrants.

AIM ImmunoTech Inc. has updated its bylaws to change the voting standard for shareholder proposals.

AIM ImmunoTech released a video detailing pre-clinical findings on Ampligen's potential as an antiviral treatment for Ebola virus disease.

AIM ImmunoTech Inc. announced the pricing of a registered direct offering and concurrent private placement of warrants, raising approximately $2.4 million in gross proceeds.

AIM ImmunoTech Inc. has extended its promissory note maturity date to June 30, 2027, and reported a significant increase in stockholder equity, enhancing financial flexibility for its clinical programs.

AIM ImmunoTech announces a Virtual Investor KOL Connect segment discussing Ampligen's potential in late-stage pancreatic cancer, featuring expert insights and updated clinical data.

AIM ImmunoTech Inc. has issued placement agent common stock purchase warrants as part of an inducement transaction to exercise existing warrants.

AIM ImmunoTech Inc. entered into an agreement to induce holders of existing warrants to exercise them for cash at a reduced price, in exchange for new warrants.

AIM ImmunoTech Inc. has amended its Equity Distribution Agreement with Maxim Group LLC, removing the previous $3,000,000 limit for at-the-market stock sales.

AIM ImmunoTech Inc. successfully closes its rights offering, raising approximately $1.8 million through the issuance of Series G Convertible Preferred Stock and Class G Warrants.

AIM ImmunoTech announced positive interim clinical progress from its Phase 2 DURIPANC study, combining Ampligen with Imfinzi for metastatic pancreatic cancer, showing promising safety and efficacy.

AIM ImmunoTech Inc. announced adjustments to its Class E and F common stock purchase warrants, reducing the exercise price to $1.439 per share and increasing the number of outstanding warrants to 5,561,125 following a stock dividend.

AIM ImmunoTech Inc. has furnished its January 2026 Corporate Presentation, outlining current and anticipated future activities related to Ampligen development.

AIM ImmunoTech Inc. held its 2025 Annual Meeting of Stockholders, electing five directors and ratifying its independent auditor, while an advisory vote on executive compensation passed based on votes cast but not overall shares represented.

AIM ImmunoTech Inc. has secured $2.5 million in net proceeds through a private placement of an unsecured promissory note with Streeterville Capital, LLC, carrying a 10% interest rate and significant investor protections.

AIM ImmunoTech Inc. filed an amended and restated Certificate of Incorporation, superseding prior versions.

AIM ImmunoTech Inc. announced its participation and presentation at the upcoming Maxim Growth Summit 2025 in New York.

AIM ImmunoTech Inc. announced the successful closing of its public offering, raising approximately $8.0 million through the sale of common stock and accompanying Class E and Class F warrants.

AIM ImmunoTech Inc. announced encouraging preliminary safety and efficacy results from its Phase 2 DURIPANC study, evaluating Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer.

AIM ImmunoTech Inc. has received a second warning from NYSE American for failing to meet minimum stockholders' equity requirements, despite having an accepted plan to regain compliance by June 2026.

AIM ImmunoTech Inc. announced it has regained compliance with NYSE American listing standards and will resume trading on the exchange on June 17, 2025, following a 1-for-100 reverse stock split.

AIM ImmunoTech stockholders approved a reverse stock split proposal at a special meeting held on April 30, 2025.

AIM ImmunoTech has received notice from the NYSE American that it will be delisted due to the low selling price of its common stock.

AIM ImmunoTech Inc. has entered into an equity distribution agreement with Maxim Group LLC to sell up to $3 million of its common stock through an at-the-market offering program.